Integra LifeSciences Holdings Corporation (NASDAQ:IART) Given Consensus Recommendation of “Reduce” by Analysts

Shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) have been given a consensus rating of “Reduce” by the eight analysts that are presently covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a sell recommendation, five have assigned a hold recommendation and one has assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $18.8571.

A number of research analysts have recently weighed in on IART shares. UBS Group assumed coverage on Integra LifeSciences in a research report on Tuesday, July 28th. They set a “neutral” rating and a $19.00 price objective for the company. Weiss Ratings cut Integra LifeSciences from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, July 30th. Truist Financial lifted their price objective on Integra LifeSciences from $14.00 to $19.00 and gave the stock a “hold” rating in a research note on Thursday, July 16th. BMO Capital Markets began coverage on Integra LifeSciences in a research report on Wednesday, July 8th. They set a “market perform” rating and a $19.00 target price for the company. Finally, Citigroup reissued a “neutral” rating and issued a $19.00 target price (up from $16.00) on shares of Integra LifeSciences in a report on Wednesday, July 8th.

Integra LifeSciences Trading Down 1.2%

Integra LifeSciences stock opened at $17.68 on Thursday. Integra LifeSciences has a 1 year low of $8.70 and a 1 year high of $20.49. The firm’s 50 day moving average price is $17.86 and its 200-day moving average price is $13.59. The company has a debt-to-equity ratio of 1.75, a current ratio of 3.60 and a quick ratio of 2.11. The stock has a market cap of $1.37 billion, a P/E ratio of -196.42, a PEG ratio of 1.51 and a beta of 1.21.

Integra LifeSciences (NASDAQ:IART) last issued its earnings results on Wednesday, July 29th. The life sciences company reported $0.56 earnings per share for the quarter, topping analysts’ consensus estimates of $0.48 by $0.08. The firm had revenue of $418.76 million during the quarter, compared to analyst estimates of $417.54 million. Integra LifeSciences had a negative net margin of 0.44% and a positive return on equity of 18.30%. Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. On average, equities analysts predict that Integra LifeSciences will post 2.46 earnings per share for the current fiscal year.

Institutional Trading of Integra LifeSciences

Large investors have recently made changes to their positions in the business. Rubric Capital Management LP lifted its holdings in shares of Integra LifeSciences by 1.3% in the 4th quarter. Rubric Capital Management LP now owns 7,753,934 shares of the life sciences company’s stock valued at $96,304,000 after acquiring an additional 100,000 shares during the last quarter. Paradigm Capital Management Inc. NY lifted its holdings in shares of Integra LifeSciences by 50.6% in the 1st quarter. Paradigm Capital Management Inc. NY now owns 4,012,698 shares of the life sciences company’s stock worth $37,800,000 after acquiring an additional 1,347,700 shares during the last quarter. Invesco Ltd. boosted its stake in shares of Integra LifeSciences by 0.9% during the 4th quarter. Invesco Ltd. now owns 3,522,839 shares of the life sciences company’s stock worth $43,754,000 after purchasing an additional 31,931 shares during the period. Dimensional Fund Advisors LP grew its holdings in Integra LifeSciences by 9.2% during the 3rd quarter. Dimensional Fund Advisors LP now owns 3,184,726 shares of the life sciences company’s stock valued at $45,634,000 after purchasing an additional 267,134 shares during the last quarter. Finally, State Street Corp lifted its stake in Integra LifeSciences by 0.8% in the fourth quarter. State Street Corp now owns 2,812,615 shares of the life sciences company’s stock worth $34,933,000 after purchasing an additional 21,717 shares during the last quarter. 84.78% of the stock is currently owned by institutional investors.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.